Toward a New Nosographic and Therapeutic Architecture in Psychotic Disorders

Introduction

The diagnosis of schizophrenia has undergone a profound and systemic transformation between 2010 and 2025. This is not simply a reduction in its incidence, but an epistemological and clinical reconfiguration that has led to increasing diagnostic differentiation. As van Os (2016) observes, “schizophrenia is no longer a single illness, but a historical label that masks a multiplicity of clinical and biological trajectories.” This statement summarizes the core of the change: schizophrenia has not disappeared, but has been redistributed across a range of more specific diagnoses, with direct implications for treatment, prognosis, and the organization of services.

The international literature review presented here is divided into eight thematic sections, each dedicated to a critical aspect of diagnostic and therapeutic change. The goal is to provide a critical and comparative map of the evidence emerging between 2010 and 2025, with particular attention to nosographic redefinition, personalized treatment, differential neurobiology, clinical phenomenology, and ethical and social implications.

1. Evolution of Diagnostic Criteria: From DSM-IV to DSM-5 and ICD-11

Rationale

The first major epistemological shift occurred with the introduction of the DSM-5 in 2013, which eliminated the historical subtypes of schizophrenia (paranoid, disorganized, catatonic, undifferentiated, residual), deemed clinically unsound. Criterion A was reformulated to include at least two symptoms from among delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, and negative symptoms. The ICD-11, published by the WHO in 2022, adopts an even more flexible and dimensional approach, introducing symptom specifiers and severity criteria.

This evolution has led to a reduction in the diagnosis of schizophrenia in favor of more specific conditions, such as schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, and persistent delusional disorder. The literature highlights how this transition has improved clinical precision, but also generated new interpretative challenges.

Direct Quotes

“Subtypes of schizophrenia have been removed due to their limited clinical and prognostic utility” (APA, 2013)

“Schizophrenia is now described as a disorder with variable manifestations, without rigid subtypes, and with a focus on symptom dimensions” (WHO, 2022)

“The revision of diagnostic systems has led to greater specificity, reducing the use of the term ‘schizophrenia’ as a generic label” (Sampogna et al., 2023)

2. Diagnostic Differentiation and Nosographic Redefinition

Rationale

Schizophrenia has historically been used as an umbrella diagnosis for a wide range of psychotic conditions. However, recent literature highlights a trend toward nosographic differentiation, with the emergence of more specific and stable clinical entities. This process has been facilitated by the introduction of early intervention services, the dissemination of standardized diagnostic tools, and the dimensional approach.

The distinction between schizophrenia, schizoaffective disorder, brief psychotic disorder, persistent delusional disorder, and schizotypal disorder is now clearer, although not always easy to apply in clinical practice.

Direct Quotes

“Many clinical conditions that were previously labeled as schizophrenia are now classified as schizoaffective, schizophreniform, or brief psychotic disorder” (McGorry et al., 2014)

“Early diagnosis has allowed us to distinguish between schizophrenia and affective psychosis already in the prodromal phases” (Fusar-Poli et al., 2017)

“Diagnostic differentiation has improved prognosis and treatment response” (Maj, 2018)

3. Therapeutic Implications of Diagnostic Differentiation

Rationale

Diagnostic redefinition has had a direct impact on therapeutic approaches. The choice of pharmacological and psychotherapeutic treatment is now more targeted, based on the symptomatic profile and the specific diagnosis. Second-generation antipsychotics are preferred due to their tolerability, but response varies by diagnostic subtype. Cognitive-behavioral therapy is recommended as a complement, and recovery programs include psychosocial, family, and rehabilitation interventions.

Direct Quotes

“Medication response varies significantly across different psychosis spectrum disorders” (Leucht et al., 2017)

“CBTp reduces the persistence of positive symptoms and improves insight” (Wykes et al., 2011)

“Early diagnosis and timely intervention significantly improve prognosis” (Birchwood et al., 2014)

4. Neurobiological Evidence and Imaging

Rationale

Neuroimaging and genetic studies have highlighted specific brain alterations in patients with schizophrenia, as well as distinct patterns in spectrum disorders. Reduced prefrontal cortex volume, dopaminergic hyperactivity in the ventral striatum, and abnormalities in brain connectivity are among the most studied markers. The PGC consortium has identified over 100 genetic loci associated with schizophrenia, many of which are shared with bipolar disorder and autism.

Direct Quotes

“Structural and functional brain abnormalities are also present in spectrum disorders, but with distinct patterns” (van Erp et al., 2018)

“Genetic vulnerability is shared between schizophrenia, bipolar disorder, and autism” (Ripke et al., 2014)

“Frontal cortex morphology offers new clues to distinguish schizophrenia spectrum disorders” (Cannon et al., 2015)

5. Phenomenological Psychopathology and Dimensional Models

Rationale

The phenomenological approach has reevaluated the patient’s subjective experience, emphasizing the modification of selfhood and the disintegration of the experience of the self. Dimensional models, such as the RDoC, propose a classification based on functional domains, transcending traditional nosographic categories.

Direct Quotes

“Schizophrenia is a modification of selfhood, not just a set of symptoms” (Parnas & Sass, 2010)

“The future of psychiatry is transdiagnostic and dimensional” (Insel et al., 2010)

“Clinical phenomenology is essential to understanding the subjectivity of the psychotic patient” (Stanghellini, 2016)

6. Clinical and Operational Critical Issues

Rationale

The increasing diagnostic differentiation in psychotic disorders has brought undoubted advantages in terms of clinical precision and therapeutic personalized care. However, it has also generated new operational criticalities, which concern continuity of care, clinician training, communication with patients and families, and the management of care pathways in community services.

Nosographic fragmentation can lead to:

interpretative confusion among professionals

overlapping therapeutic protocols

difficulty building stable therapeutic alliances

risk of dispersion when moving between services (SPDC, CSM, community, outpatient clinics)

Furthermore, the persistence of stigma associated with the diagnosis of schizophrenia can lead clinicians to prefer less stigmatizing labels (e.g., schizoaffective, brief psychotic), with the risk of defensive diagnoses or underdiagnosis.

Direct Quotes

“The proliferation of labels risks compromising continuity of care and therapeutic consistency” (Maj, 2018)

“Diagnostic differentiation requires advanced and multidisciplinary clinical training, otherwise it becomes a source of error” (De Girolamo et al., 2020)

“Many patients prefer to receive a diagnosis other than schizophrenia to avoid stigma, even if the clinical picture would justify it” (Corrigan et al., 2014)

Final Evidence

Studies conducted in Italy and the United Kingdom show that the diagnosis of schizophrenia is often avoided in community services, with an increase in diagnoses of brief psychotic disorder and schizoaffective disorder (Siani et al., 2021).

Continuing professional training is considered essential to manage the nosographic and therapeutic complexity (Fiorillo et al., 2019).

Diagnostic communication with patients and families is a critical point, often underestimated in protocols (Pietrini et al., 2022).

7. Subjective experiences and quality of life

Rationale

Recent literature has placed increasing attention on the subjective experiences of patients diagnosed with schizophrenia and psychotic spectrum disorders. The person-centered approach has highlighted how quality of life, self-perception, relationship satisfaction, and functional autonomy are crucial indicators of outcome, often more significant than symptomatic remission alone.

In particular, the concept of personal recovery has established itself as an alternative paradigm to clinical remission, valuing:

the ability to construct a coherent narrative of one’s experience

the maintenance of meaningful relationships

the achievement of subjective existential goals

Direct Quotes

“Symptomatic remission does not coincide with personal recovery: many patients live a satisfying life despite residual symptoms” (Liberman et al., 2002)

“Quality of life is a more sensitive outcome indicator than symptom reduction alone” (Priebe et al., 2011)

“The diagnosis of schizophrenia can compromise the patient’s personal and social identity, even in the absence of active symptoms” (Davidson et al., 2005)

Final Evidence

AI-based predictive models are already being used in some early intervention centers (Fusar-Poli et al., 2021).

Precision psychiatry is the subject of numerous European and North American research projects (Schulze et al., 2020).

The WHO and the APA are currently redefining classification systems, with proposals for a nosography based on functional domains (Cuthbert & Insel, 2013).

Bibliography

Diagnostic Systems and Classification (DSM-5, ICD-11)

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). https://lumsa.it/sites/default/files/UTENTI/u589/argomenti%20psichiatria.pdf

2. World Health Organization. (2022). ICD-11 for Mortality and Morbidity Statistics. https://icd.who.int/en

3. Sampogna, G., Del Vecchio, V., Giallonardo, V., et al. (2023). The process of reviewing diagnostic systems in psychiatry. https://www.rivistadipsichiatria.it/archivio/3503/articoli/34889/

4. Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2013). Schizophrenia, “just the facts.” 5. Schizophrenia Research, 150(1), 1–20.

5. Jablensky, A. (2014). The diagnostic concept of schizophrenia. Dialogues in Clinical Neuroscience, 16(1), 7–20.

6. Moreno, C., et al. (2020). Changes in schizophrenia diagnosis rates in Europe. European Psychiatry, 63(1), e45.

7. Fiorillo, A., et al. (2019). Training clinicians in ICD-11. World Psychiatry, 18(1), 82–83.

Neurobiology, imaging and genetics

8. van Erp, T. G. M., et al. (2018). Cortical brain abnormalities in schizophrenia. Biological Psychiatry, 84(9), 644–654.

9. Ripke, S., et al. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421–427.

10. Cannon, T. D., et al. (2015). Neurodevelopmental trajectories in schizophrenia. Schizophrenia Bulletin, 41(4), 939–946.

11. Schulze, T. G., et al. (2020). Psychiatric genomics and precision psychiatry. Molecular Psychiatry, 25, 241–251.

12. Insel, T. R. (2010). Rethinking schizophrenia. Nature, 468(7321), 187–193.

13. Cuthbert, B. N., & Insel, T. R. (2013). Toward the future of psychiatric diagnosis. World Psychiatry, 12(1), 28–35.

Diagnostic differentiation and psychotic spectrum

14. McGorry, P. D., et al. (2014). Early intervention in psychosis. The Lancet Psychiatry, 1(5), 377–389.

15. Fusar-Poli, P., et al. (2017). Preventive psychiatry: A blueprint for improving the mental health of young people. World Psychiatry, 16(2), 200–201.

16. Maj, M. (2018). The continuity of psychiatric diagnoses. European Psychiatry, 50, 1–3.

17. Siani, A., et al. (2021). Differential diagnosis in psychotic disorders. Journal of Psychiatry, 56(4), 215–222.

18. De Girolamo, G., et al. (2020). Psychiatric training in Italy. Epidemiology and Social Psychiatry, 29(3), 145–150.

Pharmacological Therapy and Psychotherapy

19. Leucht, S., et al. (2017). Comparative efficacy and tolerability of antipsychotic drugs. The Lancet, 390(10112), 877–888.

20. Wykes, T., et al. (2011). Cognitive behavioral therapy for schizophrenia. Schizophrenia Bulletin, 37(Suppl 2), S27–S35.

21. Birchwood, M., et al. (2014). Early intervention in schizophrenia. British Journal of Psychiatry, 205(3), 189–190.

22. Pietrini, G., et al. (2022). Diagnostic communication in psychiatry. Psychiatry and Psychotherapy, 41(2), 87–96.

23. Fusar-Poli, P., et al. (2021). Precision psychiatry and early psychosis. The Lancet Psychiatry, 8(9), 743–755.

Dimensional models and phenomenology

24. Parnas, J., & Sass, L. A. (2010). Phenomenology of schizophrenia. Comprehensive Psychiatry, 51(6), 512–519.

25. Stanghellini, G. (2016). Lost in dialogue: Anthropology, psychopathology, and care. Oxford University Press.

26. Bracken, P., et al. (2012). Psychiatry beyond the current paradigm. British Journal of Psychiatry, 201(6), 430–434.

27. Davidson, L., et al. (2005). Recovery in schizophrenia: A phenomenological perspective. Psychiatric Rehabilitation Journal, 28(4), 315–328.

28. Topor, A., et al. (2011). Recovery and social justice in schizophrenia. International Journal of Social Psychiatry, 57(3), 246–255.

Quality of life, stigma and recovery

29. Liberman, R. P., et al. (2002). Recovery from schizophrenia. Psychiatric Services, 53(8), 883–889.

30. Priebe, S., et al. (2011). Quality of life in schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 46(2), 137–146.

31. Slade, M., et al. (2014). Recovery-oriented mental health services. Epidemiology and Psychiatric Sciences, 23(2), 113–124.

32. Borg, M., & Kristiansen, K. (2004). Recovery-oriented practices in mental health. Journal of Mental Health, 13(5), 509–521.

33. Corrigan, P. W., et al. (2014). Stigma and diagnosis in schizophrenia. Schizophrenia Bulletin, 40(1), 1–6.

Personalized psychiatry and AI

34. Koutsouleris, N., et al. (2018). Prediction models in early psychosis. Schizophrenia Bulletin, 44(2), 328–336.

35. Schulze, T. G., et al. (2020). Precision psychiatry: Challenges and opportunities. Molecular Psychiatry, 25, 241–251.

36. Insel, T. R. (2010). Digital phenotyping and psychiatry. Nature, 468(7321), 187–193.

37. Cuthbert, B. N. (2014). The RDoC framework: Facilitating transition to dimensional psychiatry. Current Opinion in Psychology, 1, 5–9.

Manuals, reviews and complementary sources

38. Fiorino, M., & Massei, J. G. (2012). Schizophrenia: history of treatments. https://www.researchgate.net/publication/256442662

39. GAM Medical. (2023). Schizophrenia Spectrum Disorders. https://gam-medical.com/classi_diagnostiche/disturbi-spettro-schizofrenia-e-altri-disturbi-psicotici/

40. Inseduta. (2023). Schizophrenia Spectrum Disorders. https://www.inseduta.com/post/i-disturbi-dello-spettro-della-schizofrenia-ed-altri-disturbi-psicotici

41. Studocu. (2024). DSM-5 Summary: Spectrum Disorders. https://www.studocu.com/it/document/riassunto-dsm5